Compare · MO vs OBIO
MO vs OBIO
Side-by-side comparison of Altria Group Inc. (MO) and Orchestra BioMed Holdings Inc. (OBIO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MO and OBIO operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- MO is the larger of the two at $124.60B, about 524.1x OBIO ($237.7M).
- Both names hit the wire about 6 times in the past 4 weeks.
- MO has more recent analyst coverage (19 ratings vs 9 for OBIO).
- Company
- Altria Group Inc.
- Orchestra BioMed Holdings Inc.
- Price
- -
- -
- Market cap
- $124.60B
- $237.7M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 6
- 6
- Recent ratings
- 19
- 9
Altria Group Inc.
Altria Group, Inc., through its subsidiaries, manufactures and sells cigarettes, oral tobacco products, and wine in the United States. It offers cigarettes primarily under the Marlboro brand; cigars principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. The company also produces and sells varietal and blended table wines, and sparkling wines under the Chateau Ste. Michelle and 14 Hands names; and imports and markets Antinori, Torres, and Villa Maria Estate wines, as well as Champagne Nicolas Feuillatte in the United States. In addition, it provides finance leasing services primarily in transportation, power generation, real estate, and manufacturing equipment industries. The company sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.
Latest MO
- Altria to Host Webcast of 2026 Annual Meeting of Shareholders
- SEC Form 10-Q filed by Altria Group Inc.
- Altria Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Altria Reports 2026 First-Quarter Results; Reaffirms Full-Year Guidance
- Altria Celebrates America by Investing in Our Growers, Communities, Employees and Iconic Brands
- Altria to Host Webcast of 2026 First-Quarter Results
- SEC Form DEFA14A filed by Altria Group Inc.
- SEC Form DEF 14A filed by Altria Group Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Altria Group Inc.
- on! PLUS™ Expands Nationwide Retail Availability
Latest OBIO
- FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
- Amendment: SEC Form SCHEDULE 13D/A filed by Orchestra BioMed Holdings Inc.
- Large owner Rtw Investments, Lp exercised 1,250,032 in-the-money shares at a strike of $0.00 and sold $132 worth of shares (32 units at $4.13) (SEC Form 4)
- SEC Form DEFA14A filed by Orchestra BioMed Holdings Inc.
- SEC Form DEF 14A filed by Orchestra BioMed Holdings Inc.
- Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
- SEC Form 4 filed by Sherman Darren
- SEC Form 4 filed by Aiello Joshua
- SEC Form 4 filed by Hochman David P
- Officer Hochman David P bought $42,900 worth of shares (10,000 units at $4.29), increasing direct ownership by 0.93% to 1,086,467 units (SEC Form 4)